Pre-Referral Rectal Artesunate to Prevent Death and Disability in Severe Malaria : A Placebo-Controlled Trial
BACKGROUND: Most malaria deaths occur in rural areas. Rapid progression from illness to death can be interrupted by prompt, effective medication. Antimalarial treatment cannot rescue terminally ill patients but could be effective if given earlier. If patients who cannot be treated orally are several hours from facilities for injections, rectal artesunate can be given before referral and acts rapidly on parasites. We investigated whether this intervention reduced mortality and permanent disability. METHODS: In Bangladesh, Ghana, and Tanzania, patients with suspected severe malaria who could not be treated orally were allocated randomly to a single artesunate (n=8954) or placebo (n=8872) suppository by taking the next numbered box, then referred to clinics at which injections could be given. Those with antimalarial injections or negative blood smears before randomisation were excluded, leaving 12 068 patients (6072 artesunate, 5996 placebo) for analysis. Primary endpoints were mortality, assessed 7-30 days later, and permanent disability, reassessed periodically. All investigators were masked to group assignment. Analysis was by intention to treat. This study is registered in all three countries, numbers ISRCTN83979018, 46343627, and 76987662. RESULTS: Mortality was 154 of 6072 artesunate versus 177 of 5996 placebo (2.5%vs 3.0%, p=0.1). Two versus 13 (0.03%vs 0.22%, p=0.0020) were permanently disabled; total dead or disabled: 156 versus 190 (2.6%vs 3.2%, p=0.0484). There was no reduction in early mortality (56 vs 51 deaths within 6 h; median 2 h). In patients reaching clinic within 6 h (median 3 h), pre-referral artesunate had no significant effect on death after 6 h or permanent disability (71/4450 [1.6%] vs 82/4426 [1.9%], risk ratio 0.86 [95% CI 0.63-1.18], p=0.35). In patients still not in clinic after more than 6 h, however, half were still not there after more than 15 h, and pre-referral rectal artesunate significantly reduced death or permanent disability (29/1566 [1.9%] vs 57/1519 [3.8%], risk ratio 0.49 [95% CI 0.32-0.77], p=0.0013). INTERPRETATION: If patients with severe malaria cannot be treated orally and access to injections will take several hours, a single inexpensive artesunate suppository at the time of referral substantially reduces the risk of death or permanent disability. FUNDING: UNICEF/UNDP/World Bank Special Programme for Research and Training in Tropical Diseases (WHO/TDR); WHO Global Malaria Programme (WHO/GMP); Sall Family Foundation; the European Union (QLRT-2000-01430); the UK Medical Research Council; USAID; Irish Aid; the Karolinska Institute; and the University of Oxford Clinical Trial Service Unit (CTSU).
Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Format: | Journal Article biblioteca |
Language: | EN |
Published: |
2009-02-14
|
Subjects: | Rectal Administration, Adolescent, Adult, Antimalarials, Artemisinins, Child, Preschool Child, Disabled Persons, Female, Humans, Infant, Falciparum Malaria, Vivax Malaria, Male, Placebos, Rural Health Services, Suppositories, Young Adult, |
Online Access: | http://hdl.handle.net/10986/5086 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
id |
dig-okr-109865086 |
---|---|
record_format |
koha |
spelling |
dig-okr-1098650862021-04-23T14:02:20Z Pre-Referral Rectal Artesunate to Prevent Death and Disability in Severe Malaria : A Placebo-Controlled Trial Gomes, M. F. Faiz, M. A. Gyapong, J. O. Warsame, M. Agbenyega, T. Babiker, A. Baiden, F. Yunus, E. B. Binka, F. Clerk, C. Folb, P. Hassan, R. Hossain, M. A. Kimbute, O. Kitua, A. Krishna, S. Makasi, C. Mensah, N. Mrango, Z. Olliaro, P. Peto, R. Peto, T. J. Rahman, M. R. Ribeiro, I. Samad, R. White, N. J. Rectal Administration Adolescent Adult Antimalarials Artemisinins Child Preschool Child Disabled Persons Female Humans Infant Falciparum Malaria Vivax Malaria Male Placebos Rural Health Services Suppositories Young Adult BACKGROUND: Most malaria deaths occur in rural areas. Rapid progression from illness to death can be interrupted by prompt, effective medication. Antimalarial treatment cannot rescue terminally ill patients but could be effective if given earlier. If patients who cannot be treated orally are several hours from facilities for injections, rectal artesunate can be given before referral and acts rapidly on parasites. We investigated whether this intervention reduced mortality and permanent disability. METHODS: In Bangladesh, Ghana, and Tanzania, patients with suspected severe malaria who could not be treated orally were allocated randomly to a single artesunate (n=8954) or placebo (n=8872) suppository by taking the next numbered box, then referred to clinics at which injections could be given. Those with antimalarial injections or negative blood smears before randomisation were excluded, leaving 12 068 patients (6072 artesunate, 5996 placebo) for analysis. Primary endpoints were mortality, assessed 7-30 days later, and permanent disability, reassessed periodically. All investigators were masked to group assignment. Analysis was by intention to treat. This study is registered in all three countries, numbers ISRCTN83979018, 46343627, and 76987662. RESULTS: Mortality was 154 of 6072 artesunate versus 177 of 5996 placebo (2.5%vs 3.0%, p=0.1). Two versus 13 (0.03%vs 0.22%, p=0.0020) were permanently disabled; total dead or disabled: 156 versus 190 (2.6%vs 3.2%, p=0.0484). There was no reduction in early mortality (56 vs 51 deaths within 6 h; median 2 h). In patients reaching clinic within 6 h (median 3 h), pre-referral artesunate had no significant effect on death after 6 h or permanent disability (71/4450 [1.6%] vs 82/4426 [1.9%], risk ratio 0.86 [95% CI 0.63-1.18], p=0.35). In patients still not in clinic after more than 6 h, however, half were still not there after more than 15 h, and pre-referral rectal artesunate significantly reduced death or permanent disability (29/1566 [1.9%] vs 57/1519 [3.8%], risk ratio 0.49 [95% CI 0.32-0.77], p=0.0013). INTERPRETATION: If patients with severe malaria cannot be treated orally and access to injections will take several hours, a single inexpensive artesunate suppository at the time of referral substantially reduces the risk of death or permanent disability. FUNDING: UNICEF/UNDP/World Bank Special Programme for Research and Training in Tropical Diseases (WHO/TDR); WHO Global Malaria Programme (WHO/GMP); Sall Family Foundation; the European Union (QLRT-2000-01430); the UK Medical Research Council; USAID; Irish Aid; the Karolinska Institute; and the University of Oxford Clinical Trial Service Unit (CTSU). 2012-03-30T07:31:13Z 2012-03-30T07:31:13Z 2009-02-14 Journal Article Lancet 1474-547X (Electronic) 0140-6736 (Linking) http://hdl.handle.net/10986/5086 EN http://creativecommons.org/licenses/by-nc-nd/3.0/igo World Bank Journal Article Bangladesh Ghana Tanzania |
institution |
Banco Mundial |
collection |
DSpace |
country |
Estados Unidos |
countrycode |
US |
component |
Bibliográfico |
access |
En linea |
databasecode |
dig-okr |
tag |
biblioteca |
region |
America del Norte |
libraryname |
Biblioteca del Banco Mundial |
language |
EN |
topic |
Rectal Administration Adolescent Adult Antimalarials Artemisinins Child Preschool Child Disabled Persons Female Humans Infant Falciparum Malaria Vivax Malaria Male Placebos Rural Health Services Suppositories Young Adult Rectal Administration Adolescent Adult Antimalarials Artemisinins Child Preschool Child Disabled Persons Female Humans Infant Falciparum Malaria Vivax Malaria Male Placebos Rural Health Services Suppositories Young Adult |
spellingShingle |
Rectal Administration Adolescent Adult Antimalarials Artemisinins Child Preschool Child Disabled Persons Female Humans Infant Falciparum Malaria Vivax Malaria Male Placebos Rural Health Services Suppositories Young Adult Rectal Administration Adolescent Adult Antimalarials Artemisinins Child Preschool Child Disabled Persons Female Humans Infant Falciparum Malaria Vivax Malaria Male Placebos Rural Health Services Suppositories Young Adult Gomes, M. F. Faiz, M. A. Gyapong, J. O. Warsame, M. Agbenyega, T. Babiker, A. Baiden, F. Yunus, E. B. Binka, F. Clerk, C. Folb, P. Hassan, R. Hossain, M. A. Kimbute, O. Kitua, A. Krishna, S. Makasi, C. Mensah, N. Mrango, Z. Olliaro, P. Peto, R. Peto, T. J. Rahman, M. R. Ribeiro, I. Samad, R. White, N. J. Pre-Referral Rectal Artesunate to Prevent Death and Disability in Severe Malaria : A Placebo-Controlled Trial |
description |
BACKGROUND: Most malaria deaths occur in rural areas. Rapid progression from illness to death can be interrupted by prompt, effective medication. Antimalarial treatment cannot rescue terminally ill patients but could be effective if given earlier. If patients who cannot be treated orally are several hours from facilities for injections, rectal artesunate can be given before referral and acts rapidly on parasites. We investigated whether this intervention reduced mortality and permanent disability. METHODS: In Bangladesh, Ghana, and Tanzania, patients with suspected severe malaria who could not be treated orally were allocated randomly to a single artesunate (n=8954) or placebo (n=8872) suppository by taking the next numbered box, then referred to clinics at which injections could be given. Those with antimalarial injections or negative blood smears before randomisation were excluded, leaving 12 068 patients (6072 artesunate, 5996 placebo) for analysis. Primary endpoints were mortality, assessed 7-30 days later, and permanent disability, reassessed periodically. All investigators were masked to group assignment. Analysis was by intention to treat. This study is registered in all three countries, numbers ISRCTN83979018, 46343627, and 76987662. RESULTS: Mortality was 154 of 6072 artesunate versus 177 of 5996 placebo (2.5%vs 3.0%, p=0.1). Two versus 13 (0.03%vs 0.22%, p=0.0020) were permanently disabled; total dead or disabled: 156 versus 190 (2.6%vs 3.2%, p=0.0484). There was no reduction in early mortality (56 vs 51 deaths within 6 h; median 2 h). In patients reaching clinic within 6 h (median 3 h), pre-referral artesunate had no significant effect on death after 6 h or permanent disability (71/4450 [1.6%] vs 82/4426 [1.9%], risk ratio 0.86 [95% CI 0.63-1.18], p=0.35). In patients still not in clinic after more than 6 h, however, half were still not there after more than 15 h, and pre-referral rectal artesunate significantly reduced death or permanent disability (29/1566 [1.9%] vs 57/1519 [3.8%], risk ratio 0.49 [95% CI 0.32-0.77], p=0.0013). INTERPRETATION: If patients with severe malaria cannot be treated orally and access to injections will take several hours, a single inexpensive artesunate suppository at the time of referral substantially reduces the risk of death or permanent disability. FUNDING: UNICEF/UNDP/World Bank Special Programme for Research and Training in Tropical Diseases (WHO/TDR); WHO Global Malaria Programme (WHO/GMP); Sall Family Foundation; the European Union (QLRT-2000-01430); the UK Medical Research Council; USAID; Irish Aid; the Karolinska Institute; and the University of Oxford Clinical Trial Service Unit (CTSU). |
format |
Journal Article |
topic_facet |
Rectal Administration Adolescent Adult Antimalarials Artemisinins Child Preschool Child Disabled Persons Female Humans Infant Falciparum Malaria Vivax Malaria Male Placebos Rural Health Services Suppositories Young Adult |
author |
Gomes, M. F. Faiz, M. A. Gyapong, J. O. Warsame, M. Agbenyega, T. Babiker, A. Baiden, F. Yunus, E. B. Binka, F. Clerk, C. Folb, P. Hassan, R. Hossain, M. A. Kimbute, O. Kitua, A. Krishna, S. Makasi, C. Mensah, N. Mrango, Z. Olliaro, P. Peto, R. Peto, T. J. Rahman, M. R. Ribeiro, I. Samad, R. White, N. J. |
author_facet |
Gomes, M. F. Faiz, M. A. Gyapong, J. O. Warsame, M. Agbenyega, T. Babiker, A. Baiden, F. Yunus, E. B. Binka, F. Clerk, C. Folb, P. Hassan, R. Hossain, M. A. Kimbute, O. Kitua, A. Krishna, S. Makasi, C. Mensah, N. Mrango, Z. Olliaro, P. Peto, R. Peto, T. J. Rahman, M. R. Ribeiro, I. Samad, R. White, N. J. |
author_sort |
Gomes, M. F. |
title |
Pre-Referral Rectal Artesunate to Prevent Death and Disability in Severe Malaria : A Placebo-Controlled Trial |
title_short |
Pre-Referral Rectal Artesunate to Prevent Death and Disability in Severe Malaria : A Placebo-Controlled Trial |
title_full |
Pre-Referral Rectal Artesunate to Prevent Death and Disability in Severe Malaria : A Placebo-Controlled Trial |
title_fullStr |
Pre-Referral Rectal Artesunate to Prevent Death and Disability in Severe Malaria : A Placebo-Controlled Trial |
title_full_unstemmed |
Pre-Referral Rectal Artesunate to Prevent Death and Disability in Severe Malaria : A Placebo-Controlled Trial |
title_sort |
pre-referral rectal artesunate to prevent death and disability in severe malaria : a placebo-controlled trial |
publishDate |
2009-02-14 |
url |
http://hdl.handle.net/10986/5086 |
work_keys_str_mv |
AT gomesmf prereferralrectalartesunatetopreventdeathanddisabilityinseveremalariaaplacebocontrolledtrial AT faizma prereferralrectalartesunatetopreventdeathanddisabilityinseveremalariaaplacebocontrolledtrial AT gyapongjo prereferralrectalartesunatetopreventdeathanddisabilityinseveremalariaaplacebocontrolledtrial AT warsamem prereferralrectalartesunatetopreventdeathanddisabilityinseveremalariaaplacebocontrolledtrial AT agbenyegat prereferralrectalartesunatetopreventdeathanddisabilityinseveremalariaaplacebocontrolledtrial AT babikera prereferralrectalartesunatetopreventdeathanddisabilityinseveremalariaaplacebocontrolledtrial AT baidenf prereferralrectalartesunatetopreventdeathanddisabilityinseveremalariaaplacebocontrolledtrial AT yunuseb prereferralrectalartesunatetopreventdeathanddisabilityinseveremalariaaplacebocontrolledtrial AT binkaf prereferralrectalartesunatetopreventdeathanddisabilityinseveremalariaaplacebocontrolledtrial AT clerkc prereferralrectalartesunatetopreventdeathanddisabilityinseveremalariaaplacebocontrolledtrial AT folbp prereferralrectalartesunatetopreventdeathanddisabilityinseveremalariaaplacebocontrolledtrial AT hassanr prereferralrectalartesunatetopreventdeathanddisabilityinseveremalariaaplacebocontrolledtrial AT hossainma prereferralrectalartesunatetopreventdeathanddisabilityinseveremalariaaplacebocontrolledtrial AT kimbuteo prereferralrectalartesunatetopreventdeathanddisabilityinseveremalariaaplacebocontrolledtrial AT kituaa prereferralrectalartesunatetopreventdeathanddisabilityinseveremalariaaplacebocontrolledtrial AT krishnas prereferralrectalartesunatetopreventdeathanddisabilityinseveremalariaaplacebocontrolledtrial AT makasic prereferralrectalartesunatetopreventdeathanddisabilityinseveremalariaaplacebocontrolledtrial AT mensahn prereferralrectalartesunatetopreventdeathanddisabilityinseveremalariaaplacebocontrolledtrial AT mrangoz prereferralrectalartesunatetopreventdeathanddisabilityinseveremalariaaplacebocontrolledtrial AT olliarop prereferralrectalartesunatetopreventdeathanddisabilityinseveremalariaaplacebocontrolledtrial AT petor prereferralrectalartesunatetopreventdeathanddisabilityinseveremalariaaplacebocontrolledtrial AT petotj prereferralrectalartesunatetopreventdeathanddisabilityinseveremalariaaplacebocontrolledtrial AT rahmanmr prereferralrectalartesunatetopreventdeathanddisabilityinseveremalariaaplacebocontrolledtrial AT ribeiroi prereferralrectalartesunatetopreventdeathanddisabilityinseveremalariaaplacebocontrolledtrial AT samadr prereferralrectalartesunatetopreventdeathanddisabilityinseveremalariaaplacebocontrolledtrial AT whitenj prereferralrectalartesunatetopreventdeathanddisabilityinseveremalariaaplacebocontrolledtrial |
_version_ |
1756571582735581184 |